Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Odainic, Olesea
ENSURE-1, NCT05134441: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis	Recruiting	3	1050	Europe, US, RoW	IMU-838 tablets, vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium	Immunic AG	Multiple Sclerosis	09/24	09/32
NCT03362294: Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS	Active, not recruiting	2	30	RoW	GA Depot 40mg once monthly, GA Depot 25mg once monthly	Mapi Pharma Ltd.	Primary Progressive Multiple Sclerosis	08/26	09/26
Gavriliuc, Mihail
ENSURE-1, NCT05134441: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis	Recruiting	3	1050	Europe, US, RoW	IMU-838 tablets, vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium	Immunic AG	Multiple Sclerosis	09/24	09/32
NCT03362294: Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS	Active, not recruiting	2	30	RoW	GA Depot 40mg once monthly, GA Depot 25mg once monthly	Mapi Pharma Ltd.	Primary Progressive Multiple Sclerosis	08/26	09/26